- Home
- AMRN vs ACIU Comparison
AMRN vs ACIU Comparison
Compare AMRN & ACIU Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- AMRN
- ACIU
- Stock Information
- Founded
- AMRN 1989
- ACIU 2003
- Country
- AMRN Ireland
- ACIU Switzerland
- Employees
- AMRN N/A
- ACIU N/A
- Industry
- AMRN Biotechnology: Pharmaceutical Preparations
- ACIU Biotechnology: Pharmaceutical Preparations
- Sector
- AMRN Health Care
- ACIU Health Care
- Exchange
- AMRN Nasdaq
- ACIU Nasdaq
- Market Cap
- AMRN 216.0M
- ACIU 213.3M
- IPO Year
- AMRN 1993
- ACIU 2016
- Fundamental
- Price
- AMRN $15.98
- ACIU $2.15
- Analyst Decision
- AMRN Strong Sell
- ACIU Strong Buy
- Analyst Count
- AMRN 1
- ACIU 1
- Target Price
- AMRN $12.00
- ACIU $12.00
- AVG Volume (30 Days)
- AMRN 69.5K
- ACIU 124.8K
- Earning Date
- AMRN 07-30-2025
- ACIU 08-05-2025
- Dividend Yield
- AMRN N/A
- ACIU N/A
- EPS Growth
- AMRN N/A
- ACIU N/A
- EPS
- AMRN N/A
- ACIU N/A
- Revenue
- AMRN $219,361,000.00
- ACIU $36,362,036.00
- Revenue This Year
- AMRN N/A
- ACIU N/A
- Revenue Next Year
- AMRN N/A
- ACIU $1,022.98
- P/E Ratio
- AMRN N/A
- ACIU N/A
- Revenue Growth
- AMRN N/A
- ACIU 86.71
- 52 Week Low
- AMRN $7.08
- ACIU $1.43
- 52 Week High
- AMRN $17.49
- ACIU $3.98
- Technical
- Relative Strength Index (RSI)
- AMRN 59.78
- ACIU 50.42
- Support Level
- AMRN $15.54
- ACIU $2.05
- Resistance Level
- AMRN $16.50
- ACIU $2.19
- Average True Range (ATR)
- AMRN 0.48
- ACIU 0.16
- MACD
- AMRN 0.08
- ACIU -0.01
- Stochastic Oscillator
- AMRN 73.06
- ACIU 23.91
About AMRN Amarin Corporation plc
Amarin Corp PLC is a biopharmaceutical company. It is focused on the commercialization and development of therapeutics to improve cardiovascular, or CV, health and reduce CV risk. Its commercialized product includes Vascepa.
About ACIU AC Immune SA
AC Immune SA is a clinical-stage biopharmaceutical company that focuses on neurodegenerative diseases. The company uses its proprietary technology platforms to discover, design, and develop novel proprietary small molecules, antibodies, and vaccines for the prevention, diagnosis, and treatment of neurodegenerative diseases associated with protein misfolding. The Company has one segment. The Company currently focuses mostly of its resources on discovering and developing therapeutic and diagnostic products targeting misfolded proteins. The company's pipeline consists of ACI-24.060, Crenezumab, ACI-35.030, Semorinemab, ACI-7104.056, and others.